What is Nucleix?
Nucleix is at the forefront of revolutionizing cancer treatment through earlier disease detection. The company's pioneering approach leverages NGS and PCR-based epigenetics, utilizing methylation-based identification for the early detection of both initial and recurring cancers. Its non-invasive EpiCheck® platform is designed for high accuracy and sensitivity, offering a seamless testing option for patients and the healthcare system. Nucleix is actively building an EpiCheck franchise, starting with its Bladder EpiCheck® kit, already marketed in Europe for bladder cancer recurrence. The company is also advancing a Lung EpiCheck test for high-risk individuals toward commercialization, alongside developing additional tests for other high-risk diseases.
How much funding has Nucleix raised?
Nucleix has raised a total of $85M across 4 funding rounds:
Unspecified
$5M
Unspecified
$3M
Other Financing Round
$55M
Other Financing Round
$22M
Unspecified (2014): $5M with participation from OrbiMed Advisors LLC
Unspecified (2016): $3M led by Aurum and OrbiMed Israel Partners
Other Financing Round (2021): $55M supported by LYFE Capital, OrbiMed, OCI Bio Investments, BlackRock, DSC Investment, Aurum Ventures Private, Lilly Asia Ventures, Zohar Zisapel, MILFAM, and RA Capital Management
Other Financing Round (2022): $22M featuring Sands Capital
Key Investors in Nucleix
OrbiMed Advisors LLC
OrbiMed Advisors LLC is a specialized investment firm dedicated to the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. They bring extensive life sciences expertise to support companies at various development stages.
BlackRock
BlackRock is a global investment management firm offering a wide range of investment products and services. They manage assets across various classes for institutional and individual investors worldwide.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on public and private healthcare and life science companies, including those developing drugs, medical devices, and diagnostics. They aim to partner with innovators to bring scientific advancements to patients.
What's next for Nucleix?
The substantial capital infusion, particularly the recent major strategic investment, positions Nucleix for accelerated growth and market penetration. This funding is expected to fuel the advancement of its diagnostic pipeline, including the commercialization of the Lung EpiCheck test and the development of further disease-specific assays. Nucleix's focus on methylation-based liquid biopsy technology addresses a critical unmet need in oncology, suggesting a strong trajectory for scaling its operations and expanding its global reach. The company's strategy appears geared towards establishing EpiCheck as a leading platform for early cancer detection and recurrence monitoring.
See full Nucleix company page
